Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...

The Macula Society is a forum for new research in retinal vascular and macular diseases. David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial demonstrating that superior ...

will be presented during a panel discussion at The Macula Society's 48 th Annual Meeting taking place February 12-15, 2025, in Charlotte Harbor, Florida. ATSN-201, a best-in-class gene therapy product ...

Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...

Macular optical coherence tomography imaging should be completed twice a year for most patients with glaucoma to detect ...

Optometrists may not surgically repair macular holes, but they play a crucial role in managing visual outcomes in these ...

Glaucoma severity affects OCT-A intrasession repeatability, in which more severe disease is associated with more variability.

Researchers at Australia's WEHI (Walter and Eliza Hall Institute) medical research center applied AI analysis to over 50,000 ...

Existing Oct CCD cameras are not built for the new uses that they are being championed for. The medical field in particular wants to use them to improve aspects of patient care such as functional ...

AI-based analysis is crucial for in-home monitoring, as the high volume of daily patient images is too large for manual ...